Key baseline demographics and disease characteristics
| Characteristic . | A+AVD, n = 664 . | ABVD, n = 670 . | Total, N = 1334 . |
|---|---|---|---|
| Male sex | 378 (57) | 398 (59) | 776 (58) |
| Age, y | 35 (18-82) | 37 (18-83) | 36 (18-83) |
| <60 | 580 (87) | 568 (85) | 1148 (86) |
| ≥60 | 84 (13) | 102 (15) | 186 (4) |
| Regions | |||
| Americas | 261 (39) | 262 (39) | 523 (39) |
| Europe | 333 (50) | 336 (50) | 669 (50) |
| Asia | 70 (11) | 72 (11) | 142 (11) |
| IPS | |||
| 0 or 1 | 141 (21) | 141 (21) | 282 (21) |
| 2 or 3 | 354 (53) | 351 (52) | 705 (53) |
| 4 to 7 | 169 (25) | 178 (27) | 347 (26) |
| ECOG performance status | |||
| 0 | 376 (57) | 378 (57) | 754 (57) |
| 1 | 260 (39) | 263 (39) | 523 (39) |
| 2 | 28 (4) | 27 (4) | 55 (4) |
| PET2 status | |||
| Positive | 47 (7) | 58 (9) | 105 (8) |
| Negative | 588 (89) | 577 (86) | 1165 (87) |
| Unknown/unavailable | 29 (4) | 35 (5) | 64 (5) |
| Characteristic . | A+AVD, n = 664 . | ABVD, n = 670 . | Total, N = 1334 . |
|---|---|---|---|
| Male sex | 378 (57) | 398 (59) | 776 (58) |
| Age, y | 35 (18-82) | 37 (18-83) | 36 (18-83) |
| <60 | 580 (87) | 568 (85) | 1148 (86) |
| ≥60 | 84 (13) | 102 (15) | 186 (4) |
| Regions | |||
| Americas | 261 (39) | 262 (39) | 523 (39) |
| Europe | 333 (50) | 336 (50) | 669 (50) |
| Asia | 70 (11) | 72 (11) | 142 (11) |
| IPS | |||
| 0 or 1 | 141 (21) | 141 (21) | 282 (21) |
| 2 or 3 | 354 (53) | 351 (52) | 705 (53) |
| 4 to 7 | 169 (25) | 178 (27) | 347 (26) |
| ECOG performance status | |||
| 0 | 376 (57) | 378 (57) | 754 (57) |
| 1 | 260 (39) | 263 (39) | 523 (39) |
| 2 | 28 (4) | 27 (4) | 55 (4) |
| PET2 status | |||
| Positive | 47 (7) | 58 (9) | 105 (8) |
| Negative | 588 (89) | 577 (86) | 1165 (87) |
| Unknown/unavailable | 29 (4) | 35 (5) | 64 (5) |
Connors et al.10 Values shown are n (%) or median (range).
ECOG, Eastern Cooperative Oncology Group.